Factor V Leiden Mutation and Other Thrombophilia Markers in Childhood Ischemic Stroke

Abstract

The aim of this study was to evaluate the association between ischemic childhood stroke and thrombophilia. The prevalence of thrombophilia risk factors in 30 unrelated children with ischemic stroke were compared with 33 age-matched control subjects. Patients and control group were tested for the presence of activated protein C (APC) resistance, antiphospholipid antibodies (APLA), increased factor VIII levels, and for the deficiency of protein C (PC), protein S (PS), and antithrombin. When APCR was detected in patients or in controls, factor V Leiden (FVL) mutation was also tested. Seventeen of 30 patients (56.6%) had at least one thrombophilia marker compared with only 5 of 33 control subjects (15.1%). Three children with ischemic stroke (10%) were affected with a combination of two or more thrombophilia markers whereas none of the children in the control group had a combination of risk factors. Seven of 30 children with ischemic stroke (23.3%) and one of 33 control subjects (3.03%) had APC resistance and in all of them FVL mutation were found. The prevalence of FVL mutation was higher among pediatric stroke patients than among control subjects (p < 0.05). None of the patients but one child from the control group (3.03%) had PS deficiency. Antithrombin and PC deficiencies and the presence of APLA and increased factor VIII levels were more frequent in the pediatric stroke patients than in controls but the difference was not statistically significant (p > 0.05). These data confirm that stroke in children is commonly associated with a combination of multiple risk factors and especially the prevalence of FVL mutation is increased in children with ischemic stroke compared with control subjects.

Keywords

Ischemic stroke Thrombophilia Factor V Leiden Child

References

Riela A , Roach E. Etiology of stroke in children. J Child Neurol 1993;8:201.

Broderick J , Talbot T , Prenger E , et al. Stroke in children within a major metropolitan area: The surprising importance of intracerebral hemorrhage. J Child Neurol 1993;8:250.

Schoenberg BS , Mellingier JF , Schoenberg DG . Cerebrovascular disease in infants and children: A study of incidence, clinical features and survival. Neurology 1978;28:763.

Daniels SR , Bates S , Lukinn RR , et al. Cerebrovascular arteriopathy (arteriosclerosis) and ischemic childhood stroke. Stroke 1982;13:360.

Giroud M , Lemesle M , Gouyon JB , et al. Cerebrovascular disease in children under 16 years of age in the city of Dijon, France: A study of incidence and clinical features from 1985 to 1993. J Clin Epidemiol 1995;48:1343.

De Veber G , Monagle P , Chan A , et al. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 1998;55:1539.

Nowak-Gottl U , Strater R , Heinecke A , et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylentetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999;94:3678.

Israels SJ , Seshia SS . Childhood stroke associated with protein C or protein S deficiency. J Pediatr 1987;111:562.

Roddy SM , Giang DW . Antiphospholipid antibodies and stroke in an infant. Pediatrics 1991;87:933.

10.

Bick RL . Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am 2003;17:115.

11.

Andrew M , David M , de Veber G , et al. Arterial thromboembolic complications in paediatric patients. Thromb Haemost 1997;78:715.

12.

Simioni P , de Ronde H , Prandoni P , et al. Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke 1995;26:885.

13.

Ganesan V , Kelsy H , Cookson J , et al. Activated protein C resistance in childhood stroke. Lancet 1996;347:260.

14.

Gurgey A. Clinical manifestations in thrombotic children with factor V Leiden mutation. Pediatr Hematol Oncol 1999;16:233.

15.

Nowak-Göttle U , Koch HG , Aschka I , et al. Resistance to activated protein C (APC) in children venous or arterial thromboembolism. Br J Haematol 1996;92:992.

16.

Hagstrom JN , Walter J , Bluebond-Langner R , et al. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr 1998;133:777.

17.

Becker S , Heller Ch , Gropp F , et al. Thrombophilic disorders in children with cerebral infarction. Lancet 1998;352:1756.

18.

McColl MD , Chalmers EA , Thomas A , et al. Factor V Leiden, prothrombin 20210G A, and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999;81:690.

19.

Riikonen RS , Vahtera EM , Kekomaki RM . Physiological anticoagulants and activated protein C resistance in childhood stroke. Acta Pediatr 1996;85:242.

20.

Kamphuisen PW , Eikenboom JC . Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001;21:731.

21.

Kyrle PA , Minar E , Hirschl M , et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457.

22.

Kurekci AE , Gokce H , Akar N. F VIII levels in children with thrombosis. Pediatr Int 2003;45:159.

23.

Andrew M. Developmental hemostasis: Relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74:415.

24.

Salomon O , Steinberg DM , Zivelin A , et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism. Arterioscler Thromb Vasc Biol 1999;19:511.

25.

Dahlback B , Carlsson M , Svensson PJ . Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C; Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004.

26.

Rees DC , Cox M , Clegg JB . World distribution of factor V Leiden. Lancet 1995;346:1133.

27.

Dahlback B. New molecular insights into the genetics of thrombophilia: Resistance to activated protein C, caused by Arg 506 to Gln mutation in factor V as a pathogenetic risk factor for venous thrombosis. Thromb Haemost 1995;74:139.

28.

Ridker PM , Hennekens CH , Lindpainter K , et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912.

29.

Halbmayer WM , Haushofer A , Angerer V , et al. APC resistance and factor V Leiden (FV:Q506) mutation in patients with ischemic cerebral events. Blood Coagul Fibrinolysis 1997;8:361.

30.

Bick RL , Kaplan H. Syndromes of thrombosis and hyper-coagulability congenital and acquired causes of thrombosis. Med Clin North Am 1998;82:409.

31.

Ganesan V , McShane MA , Liesner R , et al. Inherited prothrombotic states and ischaemic stroke in childhood. J Neurol Neurosurg Psychiatry 1998;65:508.

32.

Demir M , Vural O , Sunar H , et al. The prevalence of hereditary thrombophilia in the Trakya Region of Turkey. Yonsei Med J 2000;41:436.

33.

Zenz W , Bodo Z , Plotho J , et al. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost 1998;80:763.

34.

Levine SR , Brey RL . Neurological aspects of antiphospholipid antibody syndrome. Lupus 1996;5:347.

35.

Kenet G , Sadetzki S , Murad H , et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000;31:1283.